Dr Bradstreet at the Treating Autism Conference 9th September 2012 (Extract GcMAF Therapy)
Talking at the Treating Autism Conference 2012 (www.treatingautism.co.uk), Dr Bradstreet explains how he made the connection between HIV patients, GcMAF and autism, and how he uses GcMAF from First Immune (gcmaf.eu). He has checked the process and quality control and describes their laboratory as a boutique laboratory. He satisfies himself as to the quality, sterility and activity of the GcMAF and this has also confirmed by Prof Ruggerio in Italy. His medical paper is currently under peer review and will be published as soon as this process is completed. This describes how the presence of nagalase creates a reduction of naturally occurring GcMAF and observed reduction of nagalase from injectable GcMAF. He then goes on to describe the levels of success he is seeing in the treatment of autism using First Immune GcMAF.
Dr Bradstreet at the Treating Autism Conference 9th September 2012 (Full Version)
Dr Jeff Bradstreet in First Immune GcMAF's laboratory
Dr Bradstreet visits First Immune GcMAF's laboratory to inspect for quality control. He has now treated over 900 autistic patients using First Immune GcMAF, ranging from less than a year old to almost 40 years old. In addition, he treats cancer, ME/CFS and a broad range of disorders with GcMAF. Describing First Immune's laboratory as a boutique laboratory, he explains that this treatment is accessible to all, thanks to gcmaf.eu. He descibes his experience of the lab as top quality, excellent scientists producing a product that is pure, sterile and above all, active.
